Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.

Related Articles

Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.

Pak J Pharm Sci. 2018 Sep;31(5(Special)):2299-2302

Authors: Cui S, Zhao Q, Ye M, You D, Sun Y

Abstract
To observe and analyze the therapeutic efficacy of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients. A total of 180 elderly patients diagnosed as advanced breast cancer and treated at our hospital were enrolled. All patients were randomized into study group and control group, with 90 patients in each group. Of those, capecitabine monotherapy was administered in control group, while S-1 monotherapy was applied in study group. Clinical efficacy and safety of both groups were compared. By comparing recent therapeutic effects, results showed that the overall treatment efficacy was 51.11% in study group, while the value was 35.56% in control group, suggesting a higher therapeutic efficacy in study group (P<0.05). Also, the incidence of side effects was significantly lower in study group compared with control group (P<0.05). Moreover, quality of life was better preserved in study group (P<0.05). S-1 monotherapy was relatively effective and safe in the treatment of advanced breast cancer in elderly patients.

PMID: 30463829 [PubMed – in process]